{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T16:07:01Z","timestamp":1788538021204,"version":"build-2803163510"},"reference-count":20,"publisher":"Oxford University Press (OUP)","issue":"8","license":[{"start":{"date-parts":[[2025,4,23]],"date-time":"2025-04-23T00:00:00Z","timestamp":1745366400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,7,5]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Prior denosumab use in osteoporosis patients diminishes the BMD gains from a subsequent 12-mo romosozumab regimen. However, few studies have explored BMD gains after 24 mo of romosozumab therapy. BMD at the LS-BMD, FN-BMD, and TH-BMD and P1NP and C-terminal telopeptide of type I collagen (CTX) levels were measured after 24 mo of romosozumab therapy in 3 osteoporosis cases with prior denosumab use. The changes in cases 1-3 at 12 and 24 mo, respectively, were as follows: LS-BMD (\u22122.9% and 7.4%, 0.9% and 7.9%, 7.2% and 7.9%), FN-BMD (3.2% and 7.1%, \u22121.2% and 2.0%, 2.7% and 2.1%), and TH-BMD (\u22121.2% and 6.7%, \u22124.9% and \u22120.3%, \u22120.3% and 3.2%). The P1NP and CTX levels in case 1 (18.80\u00a0ng\/mL, 0.042\u00a0ng\/mL) peaked at 6 mo (185.00\u00a0ng\/mL, 1.280\u00a0ng\/mL) and then decreased at 24 mo by 60.8% and 65.3%, respectively. The P1NP and CTX levels in case 2 (17.10\u00a0ng\/mL, 0.059\u00a0ng\/mL) peaked at 12\u00a0mo (132.00\u00a0ng\/mL, 1.190\u00a0ng\/mL) and then decreased at 24 mo by 65.3% and 24.3%, respectively. In case 3, the P1NP and CTX levels (56.10\u00a0ng\/mL, 0.490\u00a0ng\/mL) increased at 24\u00a0mo by 233.3% and 375.5%, respectively. This is the first report of a 24-mo romosozumab regimen in a small group of osteoporosis patients with prior denosumab use having varied effects on BMD and bone turnover. Nonetheless, larger controlled studies are needed to confirm these findings.<\/jats:p>","DOI":"10.1093\/jbmrpl\/ziaf070","type":"journal-article","created":{"date-parts":[[2025,4,23]],"date-time":"2025-04-23T10:31:19Z","timestamp":1745404279000},"source":"Crossref","is-referenced-by-count":1,"title":["Impact of romosozumab treatment for 24\u00a0months after switching from denosumab: three case reports"],"prefix":"10.1093","volume":"9","author":[{"given":"Seong Hee","family":"Ahn","sequence":"first","affiliation":[{"name":"Division of Endocrinology and Metabolism, Department of Internal Medicine, Inha University Hospital, Inha University School of Medicine , Incheon 22332 ,","place":["South Korea"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seung-Eun","family":"Lee","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Ulsan University Hospital, University of Ulsan College of Medicine , Ulsan 44033 ,","place":["South Korea"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0496-247X","authenticated-orcid":false,"given":"Seung Hun","family":"Lee","sequence":"additional","affiliation":[{"name":"Division of Endocrinology and Metabolism, Department of Internal Medicine, Asan Medical Center, University of Ulsan College of Medicine , Seoul 05505 ,","place":["South Korea"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0651-2213","authenticated-orcid":false,"given":"Ha Young","family":"Kim","sequence":"additional","affiliation":[{"name":"Division of Endocrinology, Department of Internal Medicine, Gangneung Asan Hospital, University of Ulsan College of Medicine , Gangneung 25440 ,","place":["South Korea"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seongbin","family":"Hong","sequence":"additional","affiliation":[{"name":"Division of Endocrinology and Metabolism, Department of Internal Medicine, Inha University Hospital, Inha University School of Medicine , Incheon 22332 ,","place":["South Korea"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jung-Min","family":"Koh","sequence":"additional","affiliation":[{"name":"Division of Endocrinology and Metabolism, Department of Internal Medicine, Asan Medical Center, University of Ulsan College of Medicine , Seoul 05505 ,","place":["South Korea"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,4,23]]},"reference":[{"issue":"16","key":"2025072410070235400_ref1","doi-asserted-by":"publisher","first-page":"1532","DOI":"10.1056\/NEJMoa1607948","article-title":"Romosozumab treatment in postmenopausal women with osteoporosis","volume":"375","author":"Cosman","year":"2016","journal-title":"N Engl J Med"},{"issue":"5","key":"2025072410070235400_ref2","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1056\/NEJMoa1305224","article-title":"Romosozumab in postmenopausal women with low bone mineral density","volume":"370","author":"McClung","year":"2014","journal-title":"N Engl J Med"},{"issue":"15","key":"2025072410070235400_ref3","doi-asserted-by":"publisher","first-page":"1417","DOI":"10.1056\/NEJMoa1708322","article-title":"Romosozumab or alendronate for fracture prevention in women with osteoporosis","volume":"377","author":"Saag","year":"2017","journal-title":"N Engl J Med"},{"issue":"Suppl 1","key":"2025072410070235400_ref4","doi-asserted-by":"publisher","first-page":"1","DOI":"10.4158\/GL-2020-0524SUPPL","article-title":"American Association of Clinical Endocrinologists\/American College of Endocrinology Clinical Practice Guidelines for the diagnosis and treatment of postmenopausal osteoporosis-2020 update","volume":"26","author":"Camacho","year":"2020","journal-title":"Endocr Pract"},{"issue":"3","key":"2025072410070235400_ref5","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgaa048","article-title":"Pharmacological management of osteoporosis in postmenopausal women: an Endocrine Society guideline update","volume":"105","author":"Shoback","year":"2020","journal-title":"J Clin Endocrinol Metab"},{"issue":"6","key":"2025072410070235400_ref6","doi-asserted-by":"publisher","first-page":"1243","DOI":"10.1007\/s00198-021-06174-0","article-title":"Romosozumab and antiresorptive treatment: the importance of treatment sequence","volume":"33","author":"Cosman","year":"2022","journal-title":"Osteoporos Int"},{"issue":"8","key":"2025072410070235400_ref7","doi-asserted-by":"publisher","first-page":"1807","DOI":"10.1007\/s00198-022-06386-y","article-title":"Effects of prior osteoporosis treatment on the treatment response of romosozumab followed by denosumab in patients with postmenopausal osteoporosis","volume":"33","author":"Ebina","year":"2022","journal-title":"Osteoporos Int"},{"issue":"11","key":"2025072410070235400_ref8","doi-asserted-by":"publisher","first-page":"2441","DOI":"10.1007\/s00198-022-06545-1","article-title":"Impact of the duration of previous osteoporosis treatment on the effect of romosozumab in patients with postmenopausal osteoporosis","volume":"33","author":"Ebina","year":"2022","journal-title":"Osteoporos Int"},{"issue":"5","key":"2025072410070235400_ref9","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbspin.2021.105219","article-title":"Effects of prior osteoporosis treatment on 12-month treatment response of romosozumab in patients with postmenopausal osteoporosis","volume":"88","author":"Ebina","year":"2021","journal-title":"Joint Bone Spine"},{"issue":"6","key":"2025072410070235400_ref10","doi-asserted-by":"publisher","first-page":"1265","DOI":"10.1007\/s00198-021-06261-2","article-title":"Effect of the duration of previous osteoporosis treatment on the effect of romosozumab treatment","volume":"33","author":"Tominaga","year":"2022","journal-title":"Osteoporos Int"},{"issue":"12","key":"2025072410070235400_ref11","doi-asserted-by":"publisher","first-page":"2437","DOI":"10.1007\/s00198-019-05146-9","article-title":"Bone mineral density gains with a second 12-month course of romosozumab therapy following placebo or denosumab","volume":"30","author":"Kendler","year":"2019","journal-title":"Osteoporos Int"},{"issue":"9","key":"2025072410070235400_ref12","doi-asserted-by":"publisher","first-page":"1669","DOI":"10.1007\/s00198-024-07139-9","article-title":"A novel sequential treatment approach between denosumab and romosozumab in patients with severe osteoporosis","volume":"35","author":"Kumar","year":"2024","journal-title":"Osteoporos Int"},{"issue":"7","key":"2025072410070235400_ref13","doi-asserted-by":"publisher","first-page":"e10512","DOI":"10.1002\/jbm4.10512","article-title":"Skeletal responses to romosozumab after 12 months of denosumab","volume":"5","author":"McClung","year":"2021","journal-title":"JBMR Plus"},{"issue":"9999","key":"2025072410070235400_ref14","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1016\/S0140-6736(15)61120-5","article-title":"Denosumab and teriparatide transitions in postmenopausal osteoporosis (the DATA-switch study): extension of a randomised controlled trial","volume":"386","author":"Leder","year":"2015","journal-title":"Lancet"},{"issue":"9","key":"2025072410070235400_ref15","doi-asserted-by":"publisher","first-page":"1597","DOI":"10.1002\/jbmr.3735","article-title":"Bone-forming and antiresorptive effects of romosozumab in postmenopausal women with osteoporosis: bone histomorphometry and microcomputed tomography analysis after 2 and 12 months of treatment","volume":"34","author":"Chavassieux","year":"2019","journal-title":"J Bone Miner Res"},{"issue":"7","key":"2025072410070235400_ref16","doi-asserted-by":"publisher","first-page":"2498","DOI":"10.1210\/jc.2017-02669","article-title":"Effects of long-term denosumab on bone histomorphometry and mineralization in women with postmenopausal osteoporosis","volume":"103","author":"Dempster","year":"2018","journal-title":"J Clin Endocrinol Metab"},{"issue":"8","key":"2025072410070235400_ref17","doi-asserted-by":"publisher","first-page":"1397","DOI":"10.1002\/jbmr.3452","article-title":"Effects of 24 months of treatment with romosozumab followed by 12 months of denosumab or placebo in postmenopausal women with low bone mineral density: a randomized, double-blind, phase 2, parallel group study","volume":"33","author":"McClung","year":"2018","journal-title":"J Bone Miner Res"},{"issue":"7","key":"2025072410070235400_ref18","doi-asserted-by":"publisher","first-page":"1207","DOI":"10.1002\/jbmr.3962","article-title":"A single infusion of zoledronate in postmenopausal women following denosumab discontinuation results in partial conservation of bone mass gains","volume":"35","author":"Everts-Graber","year":"2020","journal-title":"J Bone Miner Res"},{"issue":"10","key":"2025072410070235400_ref19","doi-asserted-by":"publisher","first-page":"1858","DOI":"10.1002\/jbmr.4098","article-title":"Treatment with zoledronate subsequent to denosumab in osteoporosis: a randomized trial","volume":"35","author":"Solling","year":"2020","journal-title":"J Bone Miner Res"},{"issue":"6","key":"2025072410070235400_ref20","doi-asserted-by":"publisher","first-page":"1084","DOI":"10.1111\/bcp.13766","article-title":"Osteoanabolic and dual action drugs","volume":"85","author":"Tabacco","year":"2019","journal-title":"Br J Clin Pharmacol"}],"container-title":["JBMR Plus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jbmrplus\/advance-article-pdf\/doi\/10.1093\/jbmrpl\/ziaf070\/62993340\/ziaf070.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jbmrplus\/article-pdf\/9\/8\/ziaf070\/62993340\/ziaf070.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jbmrplus\/article-pdf\/9\/8\/ziaf070\/62993340\/ziaf070.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,24]],"date-time":"2025-07-24T14:07:09Z","timestamp":1753366029000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jbmrplus\/article\/doi\/10.1093\/jbmrpl\/ziaf070\/8118567"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,23]]},"references-count":20,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2025,7,5]]}},"URL":"https:\/\/doi.org\/10.1093\/jbmrpl\/ziaf070","relation":{},"ISSN":["2473-4039"],"issn-type":[{"value":"2473-4039","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,8]]},"published":{"date-parts":[[2025,4,23]]},"article-number":"ziaf070"}}